D.E. Shaw & Co
ENTA icon

D.E. Shaw & Co’s Enanta Pharmaceuticals ENTA Stock Holding History

D.E. Shaw & Co’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,000
Closed -$580K – 3780
2018
Q2 		$580K Hold
5,000
– – ﹤0.01% 3031
2018
Q1 		$405K Buy
+5,000
New +$385K ﹤0.01% 2982

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co's ENTA Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Enanta Pharmaceuticals (ENTA) stake by 51% in Q2 2026, selling an estimated $489K and leaving 34,539 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #4176.

D.E. Shaw & Co first reported a position in ENTA in Q3 2014 and has held it in 38 quarters since. The position peaked at $9.96M in Q1 2024. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • D.E. Shaw & Co held 34,539 shares of Enanta Pharmaceuticals worth $504K as of Q2 2026.
  • D.E. Shaw & Co sold 36,345 Enanta Pharmaceuticals shares in Q2 2026, an estimated $489K.
  • Enanta Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4176 holding.
  • D.E. Shaw & Co first reported a position in Enanta Pharmaceuticals in Q3 2014 and has held it in 38 quarters since.
  • D.E. Shaw & Co's Enanta Pharmaceuticals position peaked at $9.96M in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.